Peptide-drug & small-molecule-drug conjugates
Like an ADC but with a small targeting peptide instead of an antibody, so it penetrates tumours faster and is cheaper to make.
Overview
Peptide-drug conjugates replace the antibody of an ADC with a short or bicyclic peptide that binds the target, giving rapid tumour penetration and renal clearance, with a short half-life that reduces systemic exposure and cheaper synthesis. Examples include melflufen (Pepaxto, withdrawn in the US), lutetium radioligands (technically peptide-radionuclide conjugates), and clinical-stage PDCs such as BT8009 zelenectide pevedotin, a Nectin-4 Bicycle toxin conjugate, and CBX-12, an exatecan-SMDC. Bicycle's zelenectide pevedotin is in phase 2/3 in urothelial cancer. The same short half-life that limits toxicity also limits tumour exposure, and renal toxicity is a class concern. The simple version is an ADC with a small peptide as the address label, faster to penetrate tumours and cheaper to make.
- Bicyclic peptide binder
- Payload
How it works
Short peptide or bicyclic peptide binds the target; short half-life reduces systemic exposure.
- Rapid penetration, renal clearance
- Cheaper synthesis
- Short half-life limits tumour exposure
- Renal toxicity
Latest papers
topQuery for this technology: (TITLE:"peptide-drug conjugate" OR ABSTRACT:"peptide-drug conjugate" OR TITLE:"peptide drug conjugate" OR ABSTRACT:"peptide drug conjugate" OR TITLE:"bicycle toxin conjugate" OR ABSTRACT:"bicycle toxin conjugate"). Results are unfiltered search hits about Peptide-drug & small-molecule-drug conjugates, not a curated reading list.
Similar pages
not linked directly; found by shared links- IndicationUrothelial cancer
Shares Nectin-4, A liver-cleared Nectin-4 tracer for urothelial cancer.